Targeting inflammation in depression: Ketamine as an anti-inflammatory antidepressant in psychiatric emergency
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Major depressive disorder (MDD) is a common psychiatric disorder with multifactorial aetiology and complex pathophysiology. Despite availability of various pharmacological and non-pharmacological therapeutic strategies, treatment resistant depression (TRD) remains a significant challenge with specific concern for those patients with severe depressive symptoms in particular suicidal ideations who require immediate and effective intervention. Inflammation has been widely studied for its association with MDD and treatment response. Ketamine known as a dissociative anaesthetic has a novel rapid-acting antidepressant effect at lower doses. Anti-inflammatory actions of ketamine appear to play a role in mechanisms underlying its antidepressant effects. Considering the rapid antidepressant action of ketamine, this review provides a brief overview of antidepressant properties of ketamine as well as its effects on peripheral and central inflammation to better understand the mechanisms underlying the therapeutic action of ketamine as an anti-inflammatory antidepressant target in psychiatric emergency. Development of effective medications, which act rapidly with dual effect on both inflammation and MDD would be of a significant clinical importance for a successful and personalised treatment of inflammatory-induced TRD and suicidal thoughts and behaviour.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Towards a glutamate hypothesis of depression
Sanacora, G., Treccani, G., & Popoli, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.07.036 · Cited by 1,036
Daly, E. J., Trivedi, M. H., Janik, A., Li, H., Zhang, Y., Li, X., Lane, R., Lim, P., Duca, A. R., Hough, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.1189 · Cited by 795
Steiner, J., Bielau, H., Brisch, R., Danos, P., Ullrich, O., Mawrin, C., Bernstein, H.-G., & Bogerts, B. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.10.013 · Cited by 791
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3739 · Cited by 718
Wilkinson, S. T., Ballard, E. D., Bloch, M. H., Mathew, S. J., Murrough, J. W., Feder, A., Sos, P., Wang, G., Zarate, C. A., & Sanacora, G. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040472 · Cited by 696
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Price, R. B., Nock, M. K., Charney, D. S., & Mathew, S. J. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.04.029 · Cited by 600
DiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Side-effects associated with ketamine use in depression: a systematic review
Short, B., Fong, J., Galvez, V., Shelker, W., & Loo, C. K. (2018) · The Lancet Psychiatry · doi:10.1016/s2215-0366(17)30272-9 · Cited by 558
Torres-Platas, S. G., Cruceanu, C., Chen, G. G., Turecki, G., & Mechawar, N. (2014) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.05.007 · Cited by 545
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
Walker, A. K., Budac, D. P., Bisulco, S., Lee, A. W., Smith, R. A., Beenders, B., Kelley, K. W., & Dantzer, R. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.71 · Cited by 432
Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa068 · Cited by 418
Phillips, J. L., Norris, S., Talbot, J., Birmingham, M., Hatchard, T., Ortiz, A., Owoeye, O., Batten, L. A., & Blier, P. (2019) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18070834 · Cited by 418
Quinolinic acid: an endogenous neurotoxin with multiple targets
Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/104024 · Cited by 394
Zhou, W., Wang, N., Yang, C., Li, X.-M., Zhou, Z.-Q., & Yang, J.-J. (2014) · European Psychiatry · doi:10.1016/j.eurpsy.2013.10.005 · Cited by 390
Kishimoto, T., Chawla, J. M., Hagi, K., Zarate, C. A., Kane, J. M., Bauer, M., & Correll, C. U. (2016) · Psychological Medicine · doi:10.1017/s0033291716000064 · Cited by 359
R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine
Zhang, J.-C., Li, S.-X., & Hashimoto, K. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2013.11.033 · Cited by 357
Connecting inflammation with glutamate agonism in suicidality
Erhardt, S., Lim, C. K., Linderholm, K. R., Janelidze, S., Lindqvist, D., Samuelsson, M., Lundberg, K., Postolache, T. T., Träskman-Bendz, L., Guillemin, G. J., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.248 · Cited by 345
Esketamine for Treatment-Resistant Depression — First FDA-Approved Antidepressant in a New Class
Kim, J., Farchione, T., Potter, A., Chen, Q., & Temple, R. (2019) · New England Journal of Medicine · doi:10.1056/nejmp1903305 · Cited by 333
Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., et al. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.19m12891 · Cited by 308
Bay-Richter, C., Linderholm, K. R., Lim, C. K., Samuelsson, M., Träskman-Bendz, L., Guillemin, G. J., Erhardt, S., & Brundin, L. (2015) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2014.07.012 · Cited by 304
Kynurenine pathway in depression: a systematic review and meta-analysis
Ogyu, K., Kubo, K., Noda, Y., Iwata, Y., Tsugawa, S., Omura, Y., Wada, M., Tarumi, R., Plitman, E., Moriguchi, S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.03.023 · Cited by 301
Ballard, E. D., Ionescu, D. F., Vande Voort, J. L., Niciu, M. J., Richards, E. M., Luckenbaugh, D. A., Brutsché, N. E., Ameli, R., Furey, M. L., & Zarate, C. A. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.027 · Cited by 286
Treatment-resistant depression and suicidality
Bergfeld, I. O., Mantione, M., Figee, M., Schuurman, P. R., Lok, A., & Denys, D. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.04.016 · Cited by 256
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256
Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine
Fukumoto, K., Toki, H., Iijima, M., Hashihayata, T., Yamaguchi, J.-I., Hashimoto, K., & Chaki, S. (2017) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.116.239228 · Cited by 252
Nettis, M. A., Lombardo, G., Hastings, C., Zajkowska, Z., Mariani, N., Nikkheslat, N., Worrell, C., Enache, D., McLaughlin, A., Kose, M., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00948-6 · Cited by 235
Self-citationPitharouli, M. C., Hagenaars, S. P., Glanville, K. P., Coleman, J. R. I., Hotopf, M., Lewis, C. M., & Pariante, C. M. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060947 · Cited by 218
Matveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
Peripheral Blood Cell–Stratified Subgroups of Inflamed Depression
Lynall, M.-E., Turner, L., Bhatti, J., Cavanagh, J., de Boer, P., Mondelli, V., Jones, D., Drevets, W. C., Cowen, P., Harrison, N. A., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.11.017 · Cited by 187
Modulation of the antidepressant effects of ketamine by the mTORC1 inhibitor rapamycin
Abdallah, C. G., Averill, L. A., Gueorguieva, R., Goktas, S., Purohit, P., Ranganathan, M., Sherif, M., Ahn, K.-H., D’Souza, D. C., Formica, R., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0644-9 · Cited by 184
Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism
Williams, N. R., Heifets, B. D., Bentzley, B. S., Blasey, C., Sudheimer, K. D., Hawkins, J., Lyons, D. M., & Schatzberg, A. F. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0503-4 · Cited by 174
Yang, C., Hu, Y.-M., Zhou, Z.-Q., Zhang, G.-F., & Yang, J.-J. (2013) · Upsala Journal of Medical Sciences · doi:10.3109/03009734.2012.724118 · Cited by 173
Opioid system is necessary but not sufficient for antidepressive actions of ketamine in rodents
Klein, M. E., Chandra, J., Sheriff, S., & Malinow, R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1916570117 · Cited by 156
The role of inflammatory cytokines in suicidal behavior: A systematic review
Serafini, G., Pompili, M., Elena Seretti, M., Stefani, H., Palermo, M., Coryell, W., & Girardi, P. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.06.002 · Cited by 151
Nikkheslat, N., Zunszain, P. A., Horowitz, M. A., Barbosa, I. G., Parker, J. A., Myint, A.-M., Schwarz, M. J., Tylee, A. T., Carvalho, L. A., & Pariante, C. M. (2015) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2015.02.002 · Cited by 147
Self-citationTan, S., Wang, Y., Chen, K., Long, Z., & Zou, J. (2017) · Biological & Pharmaceutical Bulletin · doi:10.1248/bpb.b17-00131 · Cited by 142
Phillips, J. L., Norris, S., Talbot, J., Hatchard, T., Ortiz, A., Birmingham, M., Owoeye, O., Batten, L. A., & Blier, P. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-019-0570-x · Cited by 139
Molecular Pharmacology and Neurobiology of Rapid-Acting Antidepressants
Gould, T. D., Zarate, C. A., & Thompson, S. M. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052811 · Cited by 133
Childhood trauma, HPA axis activity and antidepressant response in patients with depression
Nikkheslat, N., McLaughlin, A. P., Hastings, C., Zajkowska, Z., Nettis, M. A., Mariani, N., Enache, D., Lombardo, G., Pointon, L., Cowen, P. J., et al. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.11.024 · Cited by 124
Self-citationAcevedo-Diaz, E. E., Cavanaugh, G. W., Greenstein, D., Kraus, C., Kadriu, B., Zarate, C. A., & Park, L. T. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.11.028 · Cited by 113
The role of adipokines in the rapid antidepressant effects of ketamine
Machado-Vieira, R., Gold, P. W., Luckenbaugh, D. A., Ballard, E. D., Richards, E. M., Henter, I. D., De Sousa, R. T., Niciu, M. J., Yuan, P., & Zarate, C. A. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.36 · Cited by 102
Shibakawa, Y. S., Sasaki, Y., Goshima, Y., Echigo, N., Kamiya, Y., Kurahashi, K., Yamada, Y., & Andoh, T. (2005) · British Journal of Anaesthesia · doi:10.1093/bja/aei256 · Cited by 96
Oral ketamine for the treatment of pain and treatment-resistant depression
Schoevers, R. A., Chaves, T. V., Balukova, S. M., Rot, M. A. H., & Kortekaas, R. (2016) · British Journal of Psychiatry · doi:10.1192/bjp.bp.115.165498 · Cited by 81
Vande Voort, J. L., Ballard, E. D., Luckenbaugh, D. A., Bernert, R. A., Richards, E. M., Niciu, M. J., Park, L. T., Machado-Vieira, R., Duncan, W. C., & Zarate, C. A. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15m10440 · Cited by 65
Research works printed but not linked: 45
- Andrade, 2017, Ketamine for depression, 4: in what dose, at what rate, by what route, for how long, and at what frequency?, J. Clin. Psychiatr., 78, e852, 10.4088/JCP.17f11738 · DOI · Paper page
- Ballard, 2015, Neural correlates of suicidal ideation and its reduction in depression, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu069 · DOI · Paper page
- Beilin, 2007, Low-dose ketamine affects immune responses in humans during the early postoperative period, British journal of anaesthesia, 99, 522, 10.1093/bja/aem218 · DOI
- Cattaneo, 2020, Whole-blood expression of inflammasome- and glucocorticoid-related mRNAs correctly separates treatment-resistant depressed patients from drug-free and responsive patients in the BIODEP study, Transl. Psychiatry, 10, 232, 10.1038/s41398-020-00874-7 · DOI · Paper page
- Chang, 2010, Lipoteichoic acid-induced TNF-α and IL-6 gene expressions and oxidative stress production in macrophages are suppressed by ketamine through downregulating Toll-like receptor 2-mediated activation oF ERK1/2 and NFκB, Shock, 33, 485, 10.1097/SHK.0b013e3181c3cea5 · DOI
- Chang, 2009, Inhibitory effects of ketamine on lipopolysaccharide-induced microglial activation, Mediat. Inflamm., 705379
- Chen, 2018, Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study, Psychiatr. Res., 269, 207, 10.1016/j.psychres.2018.08.078 · DOI · Paper page
- Cruz, 2017, Anti-inflammatory properties of anesthetic agents, Crit. Care, 21, 67, 10.1186/s13054-017-1645-x · DOI · Paper page
- Cui, 2019, Crosstalk between inflammation and glutamate system in depression: signaling pathway and molecular biomarkers for ketamine's antidepressant effect, Mol. Neurobiol., 56, 3484, 10.1007/s12035-018-1306-3 · DOI
- Dale, 2012, Does intraoperative ketamine attenuate inflammatory reactivity following surgery? A systematic review and meta-analysis, Anesth. Analg., 115, 934, 10.1213/ANE.0b013e3182662e30 · DOI · Paper page
- De Kock, 2013, Ketamine and peripheral inflammation, CNS Neurosci. Ther., 19, 403, 10.1111/cns.12104 · DOI · Paper page
- Deutschenbaur, 2016, Role of calcium, glutamate and NMDA in major depression and therapeutic application, Progress in neuro-psychopharmacology & biological psychiatry, 64, 325, 10.1016/j.pnpbp.2015.02.015 · DOI
- Dundee, 1970, Ketamine as an induction agent in anaesthetics, Lancet, 1, 1370, 10.1016/S0140-6736(70)91273-0 · DOI
- Fourrier, 2018, Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo, Trials, 19, 447, 10.1186/s13063-018-2829-7 · DOI · Paper page
- Haas, 1992, Ketamine: a review of its pharmacologic properties and use in ambulatory anesthesia, Anesth. Prog., 39, 61
- Haroon, 2018, Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder, Psychoneuroendocrinology, 95, 43, 10.1016/j.psyneuen.2018.05.026 · DOI · Paper page
- Himmerich, 2006, Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis, Biol. Psychiatr., 60, 882, 10.1016/j.biopsych.2006.03.075 · DOI
- Ho, 2019, Ketamine and active ketamine metabolites regulate STAT3 and the type I interferon pathway in human microglia: molecular mechanisms linked to the antidepressant effects of ketamine, Front. Pharmacol., 10, 1302, 10.3389/fphar.2019.01302 · DOI
- Horowitz, 2014, Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells, Int. J. Neuropsychopharmacol., 18, 10.1093/ijnp/pyu076 · DOI · Paper page
- Jin, 2019, The role of BDNF in the neuroimmune Axis regulation of mood disorders, Front. Neurol., 10, 515, 10.3389/fneur.2019.00515 · DOI · Paper page
- Kawasaki, 1999, Ketamine suppresses proinflammatory cytokine production in human whole blood in vitro, Anesth. Analg., 89, 665, 10.1213/00000539-199909000-00024 · DOI
- Loix, 2011, The anti-inflammatory effects of ketamine: state of the art, Acta Anaesthesiol. Belg., 62, 47
- Miller, 2013, Conceptual confluence: the kynurenine pathway as a common target for ketamine and the convergence of the inflammation and glutamate hypotheses of depression, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 38, 1607, 10.1038/npp.2013.140 · DOI
- Miller, 2020, Trial failures of anti-inflammatory drugs in depression, The lancet. Psychiatry, 7, 837, 10.1016/S2215-0366(20)30357-6 · DOI
- Mischel, 2021, Esketamine: a drug to treat resistant depression that brings more questions than answers, J. Clin. Psychopharmacol., 41, 233, 10.1097/JCP.0000000000001395 · DOI
- Niesters, 2014, Ketamine for chronic pain: risks and benefits, Br. J. Clin. Pharmacol., 77, 357, 10.1111/bcp.12094 · DOI · Paper page
- Nikkheslat, 2018, Neuroendocrine abnormalities in major depression: an insight into glucocorticoids, cytokines and kynurenine pathway imbalances, chapter 3, 45
- Nikkheslat, 2017, Antidepressant actions on glucocorticoid receptors, chapter 27, 2, 279
- Orsolini, 2020, Understanding the complex of suicide in depression: from research to clinics, Psychiatry investigation, 17, 207, 10.30773/pi.2019.0171 · DOI · Paper page
- Pribish, 2020, A review of nonanesthetic uses of ketamine, Anesthesiology research and practice, 5798285
- Roussabrov, 2008, Effect of ketamine on inflammatory and immune responses after short-duration surgery in obese patients, Open Anesthesiol. J., 2, 10.2174/1874321800802010040 · DOI
- Savitz, 2017, Role of kynurenine metabolism pathway activation in major depressive disorders, Current topics in behavioral neurosciences, 31, 249, 10.1007/7854_2016_12 · DOI
- Sforzini, 2019, Inflammation associated with coronary heart disease predicts onset of depression in a three-year prospective follow-up: a preliminary study, Brain Behav. Immun., 81, 659, 10.1016/j.bbi.2019.07.023 · DOI
- Sial, 2020, Ketamine: the final frontier or another depressing end?, Behav. Brain Res., 383, 112508, 10.1016/j.bbr.2020.112508 · DOI
- Singh, 2016, Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study, Biol. Psychiatr., 80, 424, 10.1016/j.biopsych.2015.10.018 · DOI · Paper page
- Talbot, 2019, Ketamine for chronic depression: two cautionary tales, J. Psychiatry Neurosci.: J. Psychiatr. Neurosci., 44, 384, 10.1503/jpn.190073 · DOI
- Thakurta, 2012, Rapid response with ketamine on suicidal cognition in resistant depression, Indian J. Psychol. Med., 34, 170, 10.4103/0253-7176.101793 · DOI · Paper page
- Wang, 2015, The rapid antidepressant effect of ketamine in rats is associated with down-regulation of pro-inflammatory cytokines in the hippocampus, Ups. J. Med. Sci., 120, 241, 10.3109/03009734.2015.1060281 · DOI · Paper page
- Wilkinson, 2017, Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression, Psychother. Psychosom., 86, 162, 10.1159/000457960 · DOI · Paper page
- Yang, 2019, Inflammatory markers and treatment outcome in treatment resistant depression: a systematic review, J. Affect. Disord., 257, 640, 10.1016/j.jad.2019.07.045 · DOI · Paper page
- Yang, 2015, Serum interleukin-6 is a predictive biomarker for ketamine's antidepressant effect in treatment-resistant patients with major depression, Biol. Psychiatr., 77, 10.1016/j.biopsych.2014.06.021 · DOI · Paper page
- Yuhas, 2015, Immunomodulatory activity of ketamine in human astroglial A172 cells: possible relevance to its rapid antidepressant activity, J. Neuroimmunol., 282, 33, 10.1016/j.jneuroim.2015.03.012 · DOI
- Zhang, 2021, Immunoregulation and antidepressant effect of ketamine, Transl. Neurosci., 12, 218, 10.1515/tnsci-2020-0167 · DOI
- Zhou, 2018, Antidepressant effect of repeated ketamine administration on kynurenine pathway metabolites in patients with unipolar and bipolar depression, Brain Behav. Immun., 74, 205, 10.1016/j.bbi.2018.09.007 · DOI · Paper page
- Zunszain, 2013, Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties, Mol. Psychiatr., 18, 1236, 10.1038/mp.2013.87 · DOI · Paper page
Cited by
Ketamine Treatment for Depression: A Review
Yavi, M., Lee, H., Henter, I. D., Park, L. T., & Zarate, C. A. (2022) · Discover Mental Health · doi:10.1007/s44192-022-00012-3 · Cited by 161
“In addition, a growing literature has implicated the role of inflammation in MDD, and ketamine’s anti-inflammatory properties have thus gained increased consideration as another mechanism potentially underlying its antidepressant effects [15].”
BackgroundMandal, G., Kirkpatrick, M., Alboni, S., Mariani, N., Pariante, C. M., & Borsini, A. (2024) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae041 · Cited by 15
“Our results demonstrate that treatment of HPCs with IL-1 β or IL-6 increases levels of cytokines, as established in our previous studies (Borsini et al., 2020a, 2021, 2022).”
InfluentialSuicide prevention and ketamine: insights from computational modeling
Charlton, C. E., Karvelis, P., McIntyre, R. S., & Diaconescu, A. O. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1214018 · Cited by 7
Metadata
- Authors
- Nikkheslat, N.
- Venue
- Brain, Behavior, & Immunity - Health
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 18
- Pages
- 100383
- ISSN
- 2666-3546 (ISSN-L)
- OpenAlex
- W3213166294
- Cited by
- 71
- References
- 53
- FWCI
- 4.38
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- Wellcome Trust
- Medical Research Council
- King's College London
- Medical Research Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.